Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOCRYST PHARMACEUTICALS INC Director's Dealing 2021

May 13, 2021

31868_dirs_2021-05-13_cb053b8d-2a78-43a7-9ed2-7de96ccb54e6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-05-11

Reporting Person: Barnes Alane P (Chief Legal Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-11 Common Stock M 1648 $4.73 Acquired 111923 Direct
2021-05-11 Common Stock M 33132 $1.42 Acquired 145055 Direct
2021-05-11 Common Stock M 68000 $5.45 Acquired 213055 Direct
2021-05-11 Common Stock S 102780 $12.04 Disposed 110275 Direct
2021-05-12 Common Stock M 35852 $4.73 Acquired 146127 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-05-11 Emp. Stock Option (Right to Buy) $4.73 M 1648 Disposed 2022-03-01 Common Stock (1648) Direct
2021-05-11 Emp. Stock Option (Right to Buy) $1.42 M 33132 Disposed 2023-01-01 Common Stock (33132) Direct
2021-05-11 Emp. Stock Option (Right to Buy) $5.45 M 68000 Disposed 2023-08-08 Common Stock (68000) Direct
2021-05-12 Emp. Stock Option (Right to Buy) $4.73 M 35852 Disposed 2022-03-01 Common Stock (35852) Direct

Footnotes

F1: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

F2: The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares.

F3: The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.